Phase 4 Chronic Rhinosinusitis Trial, Not Yet Recruiting NCT06556264 Sponsor: Dr. Andrew Thamboo, MD Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Phase 4 Chronic Rhinosinusitis Trial, Not Yet Recruiting

NCT06556264
Not Yet Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 19 years of age or older
  • You must be scheduled to have a procedure called Endoscopic Sinus Surgery (a surgery performed through the nostrils to treat sinus problems)
  • You must have chronic sinusitis with nasal polyps (growths inside the nose) along with moderate-to-severe asthma, confirmed by a breathing test and your medical history

Who may not be able to join:

  • People who have had or currently have a tumour in their sinuses, nose, or airways
  • People who have taken antibiotic tablets or capsules in the month before surgery
  • People who have a known problem with their immune system not working properly
  • People who have a known autoimmune disease (where the body's immune system attacks itself)
  • People who have other specific sinus or nasal conditions besides nasal polyps, such as cystic fibrosis or certain fungal sinus infections (confirm with trial site)
  • People who have previously had a lung transplant
  • People who have a known allergy or sensitivity to a type of medicine called a monoclonal antibody or biologic
  • People who have used certain biologic medicines (such as dupilumab, omalizumab, or mepolizumab) within the 6 months before joining the trial
  • People who have any other health condition that the trial doctor feels might prevent them from safely taking part
  • People who are already taking part in another clinical study that involves a biologic treatment
  • Women who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Andrew Thamboo, St Paul's Sonis Centre Director

Phone: 604-250-4174

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Dr. Andrew Thamboo, MD
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
1 January 2025

Primary endpoints

Change in Cytokine levels such as GM-CSF, IFNg, TNFa, VEGF-A, Identification of Key Interleukins and chemokynes (10/CXCL10, MIP-1a/CCL3, RANTES/CCL5), compared with placebo in CRSwNP and asthma patients from baseline to week 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov